Xenetic Biosciences, Inc. (XBIO)
Automate Your Wheel Strategy on XBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including XBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XBIO
- Rev/Share 1.6748
- Book/Share 3.3222
- PB 1.201
- Debt/Equity 0.0
- CurrentRatio 8.2004
- ROIC -0.7548
- MktCap 6153139.0
- FreeCF/Share -1.7249
- PFCF -2.3132
- PE -1.6774
- Debt/Assets 0.0
- DivYield 0
- ROE -0.5729
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Published: March 26, 2025 by: Accesswire
Sentiment: Neutral
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has entered into a Clinical Study Agreement (the "Agreement") to support an exploratory clinical study of Xenetic's systemic DNase I candidate, XBIO-015, in patients with relapsed/refractory osteosarcoma and Ewing sarcoma.
Read More
About Xenetic Biosciences, Inc. (XBIO)
- IPO Date 2016-06-30
- Website https://www.xeneticbio.com
- Industry Biotechnology
- CEO James F. Parslow
- Employees 2